KR100254021B1 - 판토프라졸 함유 약제의 경구 투여 형태 - Google Patents

판토프라졸 함유 약제의 경구 투여 형태 Download PDF

Info

Publication number
KR100254021B1
KR100254021B1 KR1019930703898A KR930703898A KR100254021B1 KR 100254021 B1 KR100254021 B1 KR 100254021B1 KR 1019930703898 A KR1019930703898 A KR 1019930703898A KR 930703898 A KR930703898 A KR 930703898A KR 100254021 B1 KR100254021 B1 KR 100254021B1
Authority
KR
South Korea
Prior art keywords
core
physiologically acceptable
polyvinylpyrrolidone
resistant
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019930703898A
Other languages
English (en)
Korean (ko)
Other versions
KR940701256A (ko
Inventor
랑고 디트리히
하르트무트 네이
Original Assignee
서키 허버트, 울프 울리히
빅굴덴 롬베르그 케미쉐 화부리크 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4218617&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100254021(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 서키 허버트, 울프 울리히, 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 filed Critical 서키 허버트, 울프 울리히
Publication of KR940701256A publication Critical patent/KR940701256A/ko
Application granted granted Critical
Publication of KR100254021B1 publication Critical patent/KR100254021B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
KR1019930703898A 1991-06-17 1992-06-13 판토프라졸 함유 약제의 경구 투여 형태 Expired - Lifetime KR100254021B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH178891 1991-06-17
CH1788/91-0 1991-06-17
PCT/EP1992/001341 WO1992022284A1 (de) 1991-06-17 1992-06-13 Pantoprazol enthaltende orale darreichungsformen

Publications (2)

Publication Number Publication Date
KR940701256A KR940701256A (ko) 1994-05-28
KR100254021B1 true KR100254021B1 (ko) 2000-05-01

Family

ID=4218617

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930703898A Expired - Lifetime KR100254021B1 (ko) 1991-06-17 1992-06-13 판토프라졸 함유 약제의 경구 투여 형태

Country Status (34)

Country Link
US (1) US5997903A (enExample)
EP (2) EP0589981B1 (enExample)
JP (1) JP3338052B2 (enExample)
KR (1) KR100254021B1 (enExample)
CN (1) CN1037932C (enExample)
AT (1) ATE144416T1 (enExample)
AU (1) AU683411B2 (enExample)
BG (1) BG61796B1 (enExample)
CA (2) CA2524168A1 (enExample)
CZ (1) CZ281697B6 (enExample)
DE (2) DE59207438D1 (enExample)
DK (1) DK0589981T3 (enExample)
ES (1) ES2096080T3 (enExample)
FI (1) FI101598B (enExample)
GR (1) GR3022154T3 (enExample)
HK (1) HK1005851A1 (enExample)
HR (1) HRP920162B1 (enExample)
IE (1) IE77640B1 (enExample)
IL (1) IL102096A (enExample)
LV (1) LV11982B (enExample)
MX (1) MX9202961A (enExample)
NO (1) NO303714B1 (enExample)
NZ (1) NZ243147A (enExample)
PL (1) PL169951B1 (enExample)
RO (1) RO117502B1 (enExample)
RU (1) RU2089180C1 (enExample)
SI (1) SI9200111A (enExample)
SK (1) SK278566B6 (enExample)
TW (1) TW224429B (enExample)
UA (1) UA32525C2 (enExample)
WO (1) WO1992022284A1 (enExample)
YU (1) YU48263B (enExample)
ZA (1) ZA924386B (enExample)
ZW (1) ZW9392A1 (enExample)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4504000A (en) * 1993-04-27 2000-09-07 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
DE4324014C2 (de) * 1993-07-17 1995-06-08 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung einer in Wasser rekonstituierbaren Zubereitung
TW280770B (enExample) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
ATE206044T1 (de) * 1994-07-08 2001-10-15 Astrazeneca Ab Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i)
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
JP3463266B2 (ja) * 1995-09-21 2003-11-05 ファーマ パス エルエルシー 酸不安定性オメパラゾールを含有する新規組成物及びその製造方法
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
IN186245B (enExample) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
HUP0100065A2 (hu) * 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny vegyületet tartalmazó új kúp gyógyszerforma
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
US20020039597A1 (en) 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
EP1121103B1 (en) 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
JP4988088B2 (ja) * 1998-08-12 2012-08-01 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジン−２−イルメチルスルフィニル−１ｈ−ベンズイミダゾール、もしくはピリジン−２−イルメチルスルフィニル−１ｈ−ベンズイミダゾールの骨格を有する化合物、またはその薬学的に許容される塩の経口投与形組成物を固定的に組み合わせた組成物
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
HRP20020006A2 (en) 1999-06-07 2003-04-30 Altana Pharma Ag Novel preparation and administration form comprising an acid-labile active compound
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
RU2259828C2 (ru) 1999-10-20 2005-09-10 Эйсай Ко., Лтд. Способы стабилизации соединений на основе бензимидазола
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
DE69925740T2 (de) * 1999-12-16 2006-05-11 Laboratorio Medinfar-Produtos Farmacéuticos, S. A. Neue stabile mehreinheitliche substituierte Benzimidazole enthaltende pharmazeutische Präparate
SK287105B6 (sk) 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
SK287684B6 (sk) * 1999-12-20 2011-06-06 Schering Corporation Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002045692A1 (en) * 2000-12-07 2002-06-13 Altana Pharma Ag Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
BR0212951A (pt) 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US8449911B2 (en) * 2003-03-12 2013-05-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
WO2004098573A1 (en) * 2003-05-08 2004-11-18 Natco Pharma Limited An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
HRP20060016A2 (en) * 2003-07-17 2006-02-28 Dr. Reddy's Laboratories Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions having a swellable coating
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2538910A1 (en) * 2003-09-18 2005-03-24 Altana Pharma Ag Use of known active ingredients as radical scavengers
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
AU2004287373A1 (en) * 2003-10-31 2005-05-19 Dexcel Ltd. Stable lansoprazole formulation
WO2005046634A2 (de) * 2003-11-14 2005-05-26 Siegfried Generics International Ag Magensaftresistente verabreichungsform
HU227317B1 (en) * 2003-11-25 2011-03-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Enteric coated tablet containing pantoprazole
US20050244490A1 (en) * 2003-12-09 2005-11-03 Michael Otto Dosing methods for beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
WO2005076987A2 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
AU2005226357B2 (en) * 2004-03-25 2010-07-01 Astellas Pharma Inc. Composition for solid pharmaceutical preparation of solifenacin or salt thereof
NZ549838A (en) * 2004-03-26 2010-04-30 Eisai R&D Man Co Ltd Coated controlled-release preparation containing a gastric acid secretion inhibitor
HRP20120049T1 (hr) * 2004-05-07 2012-02-29 Nycomed Gmbh Farmaceutski dozirni oblik koji obuhvaća pilule kao i postupak njegove proizvodnje
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
WO2006070735A1 (ja) * 2004-12-27 2006-07-06 Astellas Pharma Inc. ソリフェナシンまたはその塩の安定な粒子状医薬組成物
MX2007008141A (es) * 2005-01-03 2007-12-10 Lupin Ltd Composicion farmaceutica de sustancias labiles en medio acido.
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2007029124A2 (en) * 2005-05-13 2007-03-15 Combino Pharm, S.L. Formulations containing pantoprazole free acid and its salts
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
WO2007037259A1 (ja) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. 生体内での崩壊性を向上させたパルス製剤
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
WO2007074856A1 (ja) 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤の製造法
WO2007080601A1 (en) 2006-01-16 2007-07-19 Jubilant Organosys Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
GB2459393B (en) 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
PL2124884T3 (pl) 2006-12-22 2020-01-31 Ironwood Pharmaceuticals, Inc. Metody i kompozycje do leczenia zaburzeń przełyku
PL2224914T3 (pl) 2007-09-14 2015-11-30 Wockhardt Ltd Kompozycje diacereiny
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
DE102010052847A1 (de) * 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
CN108057028A (zh) 2013-01-15 2018-05-22 铁木医药有限公司 片剂形式的肠溶包衣的胃内滞留口服剂型及其应用和药物组合物
WO2016126625A1 (en) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN108065443B (zh) * 2017-12-30 2020-02-28 厦门金达威维生素有限公司 斥水型双包被微胶囊及其制备方法
CN114569579B (zh) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR870009717A (ko) * 1986-04-30 1987-11-30 원본미기재 신규 경구용 약제

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR870009717A (ko) * 1986-04-30 1987-11-30 원본미기재 신규 경구용 약제

Also Published As

Publication number Publication date
YU57692A (sh) 1995-03-27
CN1037932C (zh) 1998-04-08
WO1992022284A1 (de) 1992-12-23
SI9200111A (en) 1992-12-31
CN1067809A (zh) 1993-01-13
JPH06508118A (ja) 1994-09-14
PL169951B1 (pl) 1996-09-30
MX9202961A (es) 1993-02-01
NO934648D0 (no) 1993-12-16
CZ281697B6 (cs) 1996-12-11
HRP920162A2 (en) 1996-08-31
ES2096080T3 (es) 1997-03-01
SK278566B6 (en) 1997-10-08
DK0589981T3 (da) 1997-03-17
GR3022154T3 (en) 1997-03-31
HK1005851A1 (en) 1999-01-29
IL102096A0 (en) 1993-01-14
IL102096A (en) 1996-06-18
LV11982A (lv) 1998-03-20
ZW9392A1 (en) 1993-02-17
LV11982B (lv) 1998-09-20
UA32525C2 (uk) 2001-02-15
BG61796B1 (bg) 1998-06-30
IE77640B1 (en) 1997-12-31
CA2109697C (en) 2005-11-22
FI101598B1 (fi) 1998-07-31
EP0589981B1 (de) 1996-10-23
ATE144416T1 (de) 1996-11-15
TW224429B (enExample) 1994-06-01
BG98286A (bg) 1994-08-30
CA2109697A1 (en) 1992-12-23
FI935677A0 (fi) 1993-12-16
YU48263B (sh) 1997-09-30
FI935677L (fi) 1993-12-16
IE921733A1 (en) 1992-11-18
CA2524168A1 (en) 1992-12-23
EP0589981A1 (de) 1994-04-06
SK128793A3 (en) 1994-06-08
US5997903A (en) 1999-12-07
JP3338052B2 (ja) 2002-10-28
RU2089180C1 (ru) 1997-09-10
HRP920162B1 (en) 1998-08-31
AU683411B2 (en) 1997-11-13
AU1974692A (en) 1993-01-12
NO303714B1 (no) 1998-08-24
ZA924386B (en) 1993-02-24
KR940701256A (ko) 1994-05-28
DE4219390A1 (de) 1992-12-24
CZ276493A3 (en) 1994-07-13
NZ243147A (en) 1995-12-21
DE59207438D1 (de) 1996-11-28
RO117502B1 (ro) 2002-04-30
FI101598B (fi) 1998-07-31
EP0519365A1 (de) 1992-12-23
NO934648L (no) 1993-12-16

Similar Documents

Publication Publication Date Title
KR100254021B1 (ko) 판토프라졸 함유 약제의 경구 투여 형태
EP1607088B1 (en) Controlled release composition
US6780436B1 (en) Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound
AU2010200905B2 (en) Dosage form containing pantoprazole as active ingredient
HK1005851B (en) Oral-administration forms of a medicament containing pantoprazol
US20130216617A1 (en) Pharmaceutical compositions of (r)-lansoprazole
US20090208575A1 (en) Pharmaceutical Composition Of Acid Labile Substances
EP2641594B1 (en) Enteric coated solid pharmaceutical compositions for proton pump inhibitors
US20240033224A1 (en) Enteric-coated pellet, method for preparing same and formulation comprising same
WO2005034924A1 (en) Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
WO2004066982A1 (en) Stable oral benzimidazole compositions and processes for their preparation
US20090130206A1 (en) Controlled Release Compositions of an Antidepressant Agent
US20030228363A1 (en) Stabilized pharmaceutical compositons containing benzimidazole compounds
HU227317B1 (en) Enteric coated tablet containing pantoprazole
CN101524336B (zh) 含有泮托拉唑作为活性成分的剂型
WO2006111853A2 (en) Stable solid dosage forms of acid labile drug
KR20070020977A (ko) 판토프라졸 함유 경구용 약제 제형
HU219247B (en) Oral administration form of a medicament containing pantoprazol

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19931215

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19970609

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19990415

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19991118

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20000128

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20000129

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20021218

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20031219

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20050121

Start annual number: 6

End annual number: 6

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20050824

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20000128

Comment text: Registration of Establishment

Decision date: 20060330

Request date: 20050824

Appeal identifier: 2005100002047

Appeal kind category: Confirmation of the scope of right_defensive

PR1001 Payment of annual fee

Payment date: 20060126

Start annual number: 7

End annual number: 7

J301 Trial decision

Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20050824

Effective date: 20060330

PJ1301 Trial decision

Patent event code: PJ13011S02D

Patent event date: 20060403

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20050824

Decision date: 20060330

Appeal identifier: 2005100002047

PR1001 Payment of annual fee

Payment date: 20070125

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20080122

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20090123

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20100125

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20101222

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20120109

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20120109

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20130309

Termination category: Expiration of duration